Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2018-04-26 Proxy Solicitation & In…
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2018-04-26 English
FORM 4 SUBMISSION
Director's Dealing
2018-04-18 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 26, 2018. It announces the issuance of a press release with top-line proof-of-concept data from an interim analysis of a Phase 2a trial and mentions an investor conference call with slides. The document itself does not contain detailed financial statements or substantive financial data but rather references and furnishes exhibits (press release and slides). The length is 3597 characters, which is relatively short and consistent with an announcement rather than a full report. The content fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other more specific categories like Earnings Release or Investor Presentation since it only references those materials. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-03-26 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 19, 2018, reporting the departure of a director (James A. Schoeneck) and appointment of another (Dennis Fenton) to the audit committee. The key section is Item 5.02, which relates to changes in directors or officers. There is no financial data or report attached, and the content focuses solely on management changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 3057 characters, which is consistent with a typical 8-K filing for management changes, not a full report or announcement of a report publication.
2018-03-20 English
FORM 4 SUBMISSION
Director's Dealing
2018-03-06 English
FORM 3 SUBMISSION
Director's Dealing
2018-03-06 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.